Clinical Trials

366 enrolled

Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

123 enrolled

Breast Cancer Metastatic

NCT04304352 2023-06-28

VEX

162 enrolled

Advanced Breast Cancer

NCT05764941 2023-03-27

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Unknown

100 enrolled

Breast Neoplasms

NCT00431704 2023-03-24

VinCaT

39 enrolled

Breast Neoplasms

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

HER2-negative Breast Cancer

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT02607215 2022-04-20

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

84 enrolled

Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT05131841 2021-11-23

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Phase 4 Unknown

60 enrolled

Breast Neoplasms

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

100 enrolled

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04665986 2020-12-14

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

50 enrolled

Breast Neoplasms

NCT03270007 2020-10-28

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Phase 4 Unknown

304 enrolled

Primary Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

316 enrolled

Breast Neoplasms

NCT04302441 2020-03-10

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

550 enrolled

Breast Neoplasms

NCT04143906 2019-10-30

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Phase NA Unknown

48 enrolled

HER2 Positive Breast Cancer

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

184 enrolled

Triple Negative Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Unknown

300 enrolled

Breast Cancer Organoids

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Phase 2/3 Unknown

Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT02144194 2017-02-09

TNM

65 enrolled

Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT02544243 2015-09-09

Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer

Breast Neoplasms

NCT01730677 2014-03-12

LV

150 enrolled

Breast Neoplasms

NCT01641406 2012-07-16

NACprotocol

60 enrolled

Breast Carcinoma In Situ, Carcinoma, Lobular, Inflammatory Breast Neoplasms

NCT01528826 2012-02-08

NVBOX

35 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01126138 2011-05-04

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Breast Neoplasms, Neoplasm Metastasis, Carcinoma, Ductal, Breast

NCT00764972 2008-10-21

Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer

Phase 1/2 Unknown

36 enrolled

Breast Neoplasms

NCT00159094 2008-06-02

A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer

Breast Neoplasms

NCT00430001 2008-05-09

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

300 enrolled